FORM PTO-1449	Attorney Docket Number	59419-010102
	Application Number	EV 311274278 US
INFORMATION DISCLOSURE	Filing Date	January 29, 2004
STATEMENT BY APPLICANT	Applicant(s)	NG, Mary Mah Lee et al.
·	Group Art Unit	To be assigned
(use as many sheets as necessary)	Examiner Name	To be assigned

		U.S. PA	ATENT DOCUMENTS			
EXAMINER INITIALS	DOCUMENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		_				
		-	•			
		-				

		FORE	IGN PATENT DOCUMENTS				
EXAMINER	DOCUMENT	PUBLICATION				TRANS	LATION
INITIALS	NUMBER	DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	YES	NO

	OTHER DOCUMENTS
EXAMINER INITIALS	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Berditchevski et al.; "Generation of Monoclonal Antibodies to integrin-associated Proteins;" J. Biol. Chem.; Vol. 272, No. 46; Nov 14, 1997; pp. 29174-29180
	Berthet et al.; "Role of Endoproteolytic Processing in the Adhesive and Signaling Functions of α,β, Integrin;" J. Biol. Chem.; Vol. 275, No. 43; Oct 27, 2000; pp. 33308-33313
	Borges et al.; "Platelet-derived Growth Factor Receptor β and Vascular Endothelial Growth Factor Receptor 2 Bind to the β ₃ Integrin through Its Extracellular Domain;" J. Bjol. Chem.; Vol. 275, No. 51; Dec 22, 2000; pp. 39867-39873
	Chu et al.; "Characterization of a 105-kDa plasma membrane associated glycoprotein that is involved in West Nile virus binding and infection:" Virology; Vol. 312: 2003; pp. 458-469
	Eigenthaler et al.; "A Conserved Sequence Motif in the Integrin β ₃ Cytoplasmic Domain Is Required for Its Specific Interaction with β ₃ -Endonexin;" J. Biol. Chem.; Vol. 272, No. 12; Mar 21, 1997; pp. 7693-7698
	Humphries; "Integrin Structure;" Biochemical Society Transactions; Vol. 28, Part 4; 2000; pp. 311-339
	Hynes; "Cell adhesion: old and new questions;" TCB; Vol. 9, No. 12; pp. 0962-8924
	Jenkins et al.; "Tyrosine Phosphorylation of the β, Cytoplasmic Domain Mediates Integrin-Cytoskeletal Interactions;" J. Biol. Chem.; Vol. 273, No. 22; May 29, 1998; pp. 13878-13885
	Le Naour et al.; "Severely Reduced Female Fertility in CD9-Deficient Mice;" Science; Vol. 287; Jan 14, 2000; pp. 319-321
	Lin et al.; "Integrin-mediated Activation of MAP Kinase Is Independent of FAK: Evidence for Dual Integrin Signaling Pathways in Fibroblast," J. Cell Biol.; Vol. 136, No. 6; Mar 24, 1997; pp. 1385-1395

\LA-SRV01\219189v01\59419.010101

EXAMINER DATE SIGNATURE CONSIDERED EXAMINENT. Initial if reference considered, whether or not clustion is in conformance with MFEP 609; Draw line through clustion if not in conformance and not considered, include copy of this form with next communication to applicant.

Patent and Trademant Office; U.S. DiffARTMENT OF COMMERCE

FORM PTO-1449	Attorney Docket Number	59419-010102	
	Application Number	EV 311274278 US	
INFORMATION DISCLOSURE	Filing Date	January 29, 2004	
STATEMENT BY APPLICANT	Applicant(s)	NG, Mary Mah Lee et al.	
(use as many sheets as necessary)	Group Art Unit	To be assigned	
(use as many sneets as necessary)	Examiner Name	To be assigned	

	U.S. PATENT DOCUMENTS						
EXAMINER INITIALS	DOCUMENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
					· .		
		14			l		

		FORE	IGN PATENT DOCUMENTS				
EXAMINER	DOCUMENT	PUBLICATION				TRANS	LATION
INITIALS	NUMBER	DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	YES	NO
					1		

	OTHER DOCUMENTS
EXAMINER INITIALS	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Liu et al.; "Integrin cytoplasmic domain-binding proteins;" J. Cell Sci.; Vol. 113; 2000; pp. 3563-3571
	Porter et al.; "Integrin take partners: cross-talk between integrins and other membrane receptors;" Cell Biol.; Vol. 8; Oct 1998; pp. 390-396
	Renshaw et al.; "Growth factor activation of MAP kinase requires cell adhesion;" EMBO J.; Vol. 16, No. 18; 1997; pp. 5592-5599
	Roovers et al.; "Integrating the MAP kinase signal into the G1 phase cell cycle machinery;" BioEssays; Vol. 22, No. 9; 2000; pp. 818-826
	Schneller et al.; "α,β, Integrin associates with activated insulin and PDGFβ receptors and potentiates the biological activity of PDGF;" Vol. 16, No. 18; 1997; pp. 5600-5607
	Schwartz et al.; "Interactions between mitogenic stimuli, or, a thousand and one connections;" Curr. Opin. Cell Biol.; Vol. 11; 1999; pp. 197-202
	Skinner et al.; "\$1 Integrin Binds the 16-kDa Subunit of Vacuolar H*-ATPase at a Site Important for Human Papillomavirus E5 and Platelet-derived Growth Factor Signaling;" J. Biol. Chem.; Vol. 274, No. 33; Aug 13, 1999; pp. 23119-23127
	Timpl; "Macromolecular organization of basement membranes;" Curr. Opin. Cell Biol.; Vol. 8; 1996; pp. 618-624
	Vallar et al.; "Divalent Cations Differentially Regulate Integrin α ₁₀ , Cytoplasmic Tail Binding to β ₃ and to Calcium- and Integrin- binding Protein;" J. Biol. Chem; Vol. 274, No. 24; Jun 11, 1999; pp. 17257-17266
	Varner et al.; "Integrins and cancer;" Curr. Opin. Cell Biol.; Vol. 8; 1996; pp. 724-730

\LA-SRV01\219189v01\59419.	31\219189v01\59419.010101 2		
EXAMINER	D.	ATE	
SIGNATURE		ONSIDERED	
EXAMINER: Initial if referer	ce considered, whether or not citation is in conformance with	MPEP 609; Draw line through citation if not in c	onformance and not

considered. Include copy of this form with next communication to applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE